1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Accelerated Assessment Success In EU For CSL Behring And Roche

EtranaDez Will Be And Mosunetuzumab Already Is On Fast-Track Review Pathway At EMA

 
• By Maureen Kenny

There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted. 

Investigational hemophilia B gene therapy EtranaDez has received EU fast track status • Source: Alamy

A further two investigational therapies have been granted accelerated assessment status in the EU. This brings to 11 the number of known successful applicants for this fast-track review mechanism at the European Medicines Agency this year to date. 

The two products are uniQure N.V./CSL Behring’s hemophilia B gene therapy candidate etranacogene dezaparvovec (CSL222/AMT-061 and also referred to as EtranaDez) and Roche’s mosunetuzumab for the treatment of adults...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

UroGen’s Mitomycin: Are Randomized Trials For Bladder Cancer Necessary?

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee will vote on the risk-benefit of UGN-102 for low-grade, intermediate-risk, non-muscle invasive bladder cancer based on data from a single-arm trial, but the FDA also seeks input on requiring randomized studies for future treatments.

Life After Loper: Vaping Case Shows US FDA Retains Considerable Deference

 
• By Craig Bleifer, Royce DuBiner, Max Bogost, Michael Brody, and Allyson Maur

A US Supreme Court ruling in favor of the agency in an e-cigarette case has implications for drugs and other medical products as the justices decided not to disturb the FDA’s ‘change in position’ authority, while also creating a complex new landscape.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.